©The Author(s) 2025.
World J Gastroenterol. Oct 28, 2025; 31(40): 111375
Published online Oct 28, 2025. doi: 10.3748/wjg.v31.i40.111375
Published online Oct 28, 2025. doi: 10.3748/wjg.v31.i40.111375
Figure 2 Disorders occurring in both inflammatory bowel disease and steatohepatitis associated with metabolic disorders.
SCFA: Short-chain fatty acid; LPS: Lipopolysaccharide; IL: Interleukin; TNF: Tumour necrosis factor; IBD: Inflammatory bowel disease; MASLD: Metabolic dysfunction-associated steatotic liver disease; E. coli: Escherichia coli; F. prausnitzii: Faecalibacterium prausnitzii.
- Citation: Sokal-Dembowska A, Ergan K, Jarmakiewicz-Czaja S. Role of gut microbiota in the development of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease. World J Gastroenterol 2025; 31(40): 111375
- URL: https://www.wjgnet.com/1007-9327/full/v31/i40/111375.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i40.111375